# Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)

> **NCT01352026** · PHASE2 · WITHDRAWN · sponsor: **Nantes University Hospital**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01352026
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Several therapeutic have been developed making more difficult the eligibility of patients - Recruitment of new centers wasn't possible due to competing trials
- **Last updated:** 2012-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352026, "Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01352026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*